Infezioni e Low Dose medicine

Di
Redazione
-

Bibliografia articolo pubblicato sul n.141 de L’altra medicina

INFEZIONI E LOW DOSE MEDICINE

La Farmacologia Naturale tra presente e futuro

di Alessandro Perra e Marco del Prete

 

Riferimenti bibliografici

  •  Ader R, Cohen N Psychoneuroimmunology: conditioning and stress. Annu

Rev Psychol 1993;44:53-85.

  • Ader R, Cohen N, Felten D Psychoneuroimmunology: interactions between

the nervous system and the immune system. Lancet 1995;345(8942):99-

  • 103. Ader R, Cohen N, Felten DL Brain, behavior, and immunity. Brain Behav

Immun 1987;1(1):1-6.

  • Ader R, Felten D, Cohen N Interactions between the brain and the immune

system. Annu Rev Pharmacol Toxicol 1990;30:561-602.

  • Alberto Mantovani – L’orchestra Segreta. Come fuinziona il sistema

immunitario, dai tumori al COVID. La Nave di Teso, Milano: 2021

  • Andenberg LN, Colborn T, Hayes TB, Heindel JJ, Jacobs DR Jr, Lee DH,

Shioda T, Soto AM, vom Saal FS, Welshons WV, Zoeller RT, Myers JP.

Hormones and endocrine-disrupting chemicals: low-dose effects and

nonmonotonic dose responses. Endocr Rev. 2012 Jun;33(3):378-455. doi:

10.1210/er.2011-1050. https://pubmed.ncbi.nlm.nih.gov/22419778/

  •   Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based

approach to human disease. Nat Rev Genet. 2011;12(1):56-68.

doi:10.1038/nrg2918. https://pubmed.ncbi.nlm.nih.gov/21164525/

  • Biancotto A, Wank A, Perl S, Cook W, Olnes MJ, Dagur PK, Fuchs JC,

Langweiler M, Wang E, McCoy JP. Baseline levels and temporal stability of

27 multiplexed serum cytokine concentrations in healthy subjects. PLoS

One. 2013 Dec 12;8(12):e76091. doi: 10.1371/journal.pone.0076091.

Erratum in: PLoS One. 2015;10(7):e0132870.

https://pubmed.ncbi.nlm.nih.gov/24348989/

  • Del Prete M, Lozzi A. Low Dose Medicine a infiammazione. 5 a ed. Palermo:

Nuova IPSA Editore, 2024.

  • Epstein OI. Release-activity: a long way from phenomenon to new drugs.

Bull Exp Biol Med. 2012 Nov;154(1):54-8. doi: 10.1007/s10517-012-1874-6.

https://pubmed.ncbi.nlm.nih.gov/23330090/

  •   Floris I, Appel K, Rose T, Lejeune B. 2LARTH ® , a micro-immunotherapy

medicine, exerts anti-inflammatory effects in vitro and reduces TNF-α and

IL-1β secretion. J Inflamm Res. 2018 Oct 29;11:397-405. doi:

10.2147/JIR.S174326. https://pubmed.ncbi.nlm.nih.gov/30464572/

  •   Floris I, Chenuet P, Togbe D, Volteau C, Lejeune B. Potential Role of the

Micro-Immunotherapy Medicine 2LALERG in the Treatment of Pollen-

Induced Allergic Inflammation. Dose Response. 2020 Mar

24;18(1):1559325820914092. doi: 10.1177/1559325820914092.

https://pubmed.ncbi.nlm.nih.gov/32269504/

  • Floris I, García-González V, Palomares B, Appel K, Lejeune B. The Micro-

Immunotherapy Medicine 2LARTH® Reduces Inflammation and Symptoms

of Rheumatoid Arthritis In Vivo. Int J Rheumatol. 2020 Jan

23;2020:1594573. doi: 10.1155/2020/1594573.

https://pubmed.ncbi.nlm.nih.gov/32180808/

  • García Morán GA, Parra-Medina R, Cardona AG, et al. Cytokines,

chemokines and growth factors. In: Anaya JM, Shoenfeld Y, Rojas-

Villarraga A, et al., editors. Autoimmunity: From Bench to Bedside [Internet].

Bogota (Colombia): El Rosario University Press; 2013 Jul 18. Chapter 9.

Available from: https://www.ncbi.nlm.nih.gov/books/NBK459450/

  • Gariboldi S, Palazzo M, Zanobbio L, Dusio GF, Mauro V, Solimene U,

Cardani D, Mantovani M, Rumio C. Low dose oral administration of

cytokines for treatment of allergic asthma. Pulm Pharmacol Ther. 2009

Dec;22(6):497-510. doi: 10.1016/j.pupt.2009.05.002.

https://pubmed.ncbi.nlm.nih.gov/19464382/

  • Goldman AW, Burmeister Y, Cesnulevicius K, et al. Bioregulatory systems

medicine: an innovative approach to integrating the science of molecular

networks, inflammation, and systems biology with the patient's

autoregulatory capacity? Front Physiol. 2015;6:225.

doi:10.3389/fphys.2015.00225. https://pubmed.ncbi.nlm.nih.gov/26347656/

  • Lei YM, Nair L, Alegre ML. The interplay between the intestinal microbiota

and the immune system. Clin Res Hepatol Gastroenterol. 2015 Feb;39(1):9-

  1. doi: 10.1016/j.clinre.2014.10.008.

https://pubmed.ncbi.nlm.nih.gov/25481240/

  • Lilli NL, Révy D, Robelet S, Lejeune B. Effect of the micro-immunotherapy

medicine 2LPARK® on rat primary dopaminergic neurons after 6-OHDA

injury: oxidative stress and survival evaluation in an in vitro model of

Parkinson's disease. Degener Neurol Neuromuscul Dis. 2019 Jul 8;9:79-88.

doi: 10.2147/DNND.S202966. https://pubmed.ncbi.nlm.nih.gov/31372089/

  • Stéphanou A, Fanchon E, Innominato PF, Ballesta A. Systems Biology,

Systems Medicine, Systems Pharmacology: The What and The Why. Acta

Biotheor. 2018 Dec;66(4):345-365. doi: 10.1007/s10441-018-9330-2.

https://pubmed.ncbi.nlm.nih.gov/29744615/

  • Su R, Zhang T, Wang H, Yan G, Wu R, Zhang X, Gao C, Li X, Wang C.

New sights of low dose IL-2: Restoration of immune homeostasis for viral

infection. Immunology. 2024 Mar;171(3):324-338. doi: 10.1111/imm.13719.

Epub 2023 Nov 20. PMID: 37985960.

  • Tagliacarne SC, Valsecchi C, Benazzo M, Nichelatti M, Marseglia A,

Ciprandi G, Bernasconi S. Low-dose multicomponent medication modulates

humoral and cellular immune response in an ex-vivo study on children

subjected to adenoid surgery. Immunol Lett. 2018 Nov;203:95-101. doi:

10.1016/j.imlet.2018.09.014. Epub 2018 Sep 25. PMID: 30261195.